Ananda Immunotherapeutics

Singapore, Singapore

Current immunology drugs are primarily suppressive, and typically work to address disease symptoms using inhibitory mechanisms, e.g. blocking single pathways or molecules. This poses safety risks due to generalised immune suppression, and may also limit long term durability. Our novelty relies on our ability to understand immune processes not as isolated mechanisms, but rather as integrated components of a network of networks – the immunome. We use high dimensional data and artificial intelligence to understand how immune mediated disease changes the immunome, and how to restore it using cell-based, network-wide approaches to tolerance. Unlike immune suppression, this has potential to reverse and potentially even cure disease. We are pursuing two approaches to tolerance, aimed at different unmet needs: a pharmacological approach and a cell therapy-based approach.